<DOC>
	<DOC>NCT00447863</DOC>
	<brief_summary>Levonorgestrel/ethinyl estradiol (LNG/EE) is an investigational drug that is being developed as an oral contraceptive (birth control pill). The purpose of this trial is to compare different preparations of LNG/EE by assessing the way they are absorbed into the blood.</brief_summary>
	<brief_title>Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Women aged 18 to 35 years. Healthy as determined by the investigator on the basis of medical history and screening evaluations. Must have a history of normal menstrual cycles (24 to 34 days) for the 3month period preceding entry into the study. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article. Presence, history, or family history of thrombophlebitis, thrombosis, or thromboembolitic disorders, deep vein thrombosis, pulmonary embolism, or known coagulopathy. Bethesda system report of lowgrade squamous intraepithelial lesion or greater for a cervical cytologic smear obtained within the last 3 months.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>